Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma

Mamoru Uemura, Yo Sasaki, Terumasa Yamada, Kunihito Gotoh, Hidetoshi Eguchi, Masahiko Yano, Hiroaki Ohigashi, Osamu Ishikawa, Shingi Imaoka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) is the seventh most common cancer and the third leading cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC recurrence after curative resection. This study evaluated anti-HCV antibody (Ab) titer as a prognostic indicator of HCC recurrence after curative hepatic resection. Methods: A total of 82 patients with HCC (anti-HCV Ab positive and hepatitis B surface antigen negative) who underwent curative hepatic resection were evaluated. Anti-HCV Ab titers were measured using a third-generation enzyme immunoassay, and patients were divided into high (n = 41) and low (n = 41) titer groups to compare their clinicopathological characteristics and disease-free survival. Univariate and multivariate analyses were conducted to identify risk factors for early or late recurrence. Results: Multivariate analysis showed that anti-HCV Ab titer and vascular invasion were independent prognostic factors of disease-free survival [odds ratio (OR) 1.9, p = 0.03, and OR 1.8, p = 0.04, respectively]. Subgroup analysis identified only vascular invasion as an independent prognostic factor for early recurrences that were considered residual intrahepatic metastases. Subgroup analysis identified anti-HCV Ab titer and fibrosis grade as independent prognostic factors of late recurrences that were considered to be metachronous multicentric liver carcinogenesis (OR 4.8, p = 0.04, and OR 5.2, p = 0.03, respectively). Discussion: Anti-HCV Ab titer is a predictive factor for HCC recurrence, especially the risk of late recurrence due to multicentric carcinogenesis. Prevention of liver carcinogenesis after hepatic resection for HCC might be appropriate for patients with high anti-HCV Ab titers.

Original languageEnglish
Pages (from-to)1719-1725
Number of pages7
JournalAnnals of Surgical Oncology
Volume21
Issue number5
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hepatitis C Antibodies
Hepacivirus
Viral Load
Hepatocellular Carcinoma
Recurrence
Antibodies
Serum
Odds Ratio
Liver
Carcinogenesis
Disease-Free Survival
Blood Vessels
Multivariate Analysis
Virus Diseases
Hepatitis B Surface Antigens
Immunoenzyme Techniques
Cause of Death
Neoplasms
Fibrosis
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma. / Uemura, Mamoru; Sasaki, Yo; Yamada, Terumasa; Gotoh, Kunihito; Eguchi, Hidetoshi; Yano, Masahiko; Ohigashi, Hiroaki; Ishikawa, Osamu; Imaoka, Shingi.

In: Annals of Surgical Oncology, Vol. 21, No. 5, 01.01.2014, p. 1719-1725.

Research output: Contribution to journalArticle

Uemura, M, Sasaki, Y, Yamada, T, Gotoh, K, Eguchi, H, Yano, M, Ohigashi, H, Ishikawa, O & Imaoka, S 2014, 'Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma', Annals of Surgical Oncology, vol. 21, no. 5, pp. 1719-1725. https://doi.org/10.1245/s10434-013-3417-4
Uemura, Mamoru ; Sasaki, Yo ; Yamada, Terumasa ; Gotoh, Kunihito ; Eguchi, Hidetoshi ; Yano, Masahiko ; Ohigashi, Hiroaki ; Ishikawa, Osamu ; Imaoka, Shingi. / Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma. In: Annals of Surgical Oncology. 2014 ; Vol. 21, No. 5. pp. 1719-1725.
@article{043ad3fe175a440da38821237d3ebdc1,
title = "Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma",
abstract = "Background: Hepatocellular carcinoma (HCC) is the seventh most common cancer and the third leading cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC recurrence after curative resection. This study evaluated anti-HCV antibody (Ab) titer as a prognostic indicator of HCC recurrence after curative hepatic resection. Methods: A total of 82 patients with HCC (anti-HCV Ab positive and hepatitis B surface antigen negative) who underwent curative hepatic resection were evaluated. Anti-HCV Ab titers were measured using a third-generation enzyme immunoassay, and patients were divided into high (n = 41) and low (n = 41) titer groups to compare their clinicopathological characteristics and disease-free survival. Univariate and multivariate analyses were conducted to identify risk factors for early or late recurrence. Results: Multivariate analysis showed that anti-HCV Ab titer and vascular invasion were independent prognostic factors of disease-free survival [odds ratio (OR) 1.9, p = 0.03, and OR 1.8, p = 0.04, respectively]. Subgroup analysis identified only vascular invasion as an independent prognostic factor for early recurrences that were considered residual intrahepatic metastases. Subgroup analysis identified anti-HCV Ab titer and fibrosis grade as independent prognostic factors of late recurrences that were considered to be metachronous multicentric liver carcinogenesis (OR 4.8, p = 0.04, and OR 5.2, p = 0.03, respectively). Discussion: Anti-HCV Ab titer is a predictive factor for HCC recurrence, especially the risk of late recurrence due to multicentric carcinogenesis. Prevention of liver carcinogenesis after hepatic resection for HCC might be appropriate for patients with high anti-HCV Ab titers.",
author = "Mamoru Uemura and Yo Sasaki and Terumasa Yamada and Kunihito Gotoh and Hidetoshi Eguchi and Masahiko Yano and Hiroaki Ohigashi and Osamu Ishikawa and Shingi Imaoka",
year = "2014",
month = "1",
day = "1",
doi = "10.1245/s10434-013-3417-4",
language = "English",
volume = "21",
pages = "1719--1725",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma

AU - Uemura, Mamoru

AU - Sasaki, Yo

AU - Yamada, Terumasa

AU - Gotoh, Kunihito

AU - Eguchi, Hidetoshi

AU - Yano, Masahiko

AU - Ohigashi, Hiroaki

AU - Ishikawa, Osamu

AU - Imaoka, Shingi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Hepatocellular carcinoma (HCC) is the seventh most common cancer and the third leading cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC recurrence after curative resection. This study evaluated anti-HCV antibody (Ab) titer as a prognostic indicator of HCC recurrence after curative hepatic resection. Methods: A total of 82 patients with HCC (anti-HCV Ab positive and hepatitis B surface antigen negative) who underwent curative hepatic resection were evaluated. Anti-HCV Ab titers were measured using a third-generation enzyme immunoassay, and patients were divided into high (n = 41) and low (n = 41) titer groups to compare their clinicopathological characteristics and disease-free survival. Univariate and multivariate analyses were conducted to identify risk factors for early or late recurrence. Results: Multivariate analysis showed that anti-HCV Ab titer and vascular invasion were independent prognostic factors of disease-free survival [odds ratio (OR) 1.9, p = 0.03, and OR 1.8, p = 0.04, respectively]. Subgroup analysis identified only vascular invasion as an independent prognostic factor for early recurrences that were considered residual intrahepatic metastases. Subgroup analysis identified anti-HCV Ab titer and fibrosis grade as independent prognostic factors of late recurrences that were considered to be metachronous multicentric liver carcinogenesis (OR 4.8, p = 0.04, and OR 5.2, p = 0.03, respectively). Discussion: Anti-HCV Ab titer is a predictive factor for HCC recurrence, especially the risk of late recurrence due to multicentric carcinogenesis. Prevention of liver carcinogenesis after hepatic resection for HCC might be appropriate for patients with high anti-HCV Ab titers.

AB - Background: Hepatocellular carcinoma (HCC) is the seventh most common cancer and the third leading cause of cancer deaths worldwide. Hepatitis C virus (HCV) infection is a major risk factor for HCC recurrence after curative resection. This study evaluated anti-HCV antibody (Ab) titer as a prognostic indicator of HCC recurrence after curative hepatic resection. Methods: A total of 82 patients with HCC (anti-HCV Ab positive and hepatitis B surface antigen negative) who underwent curative hepatic resection were evaluated. Anti-HCV Ab titers were measured using a third-generation enzyme immunoassay, and patients were divided into high (n = 41) and low (n = 41) titer groups to compare their clinicopathological characteristics and disease-free survival. Univariate and multivariate analyses were conducted to identify risk factors for early or late recurrence. Results: Multivariate analysis showed that anti-HCV Ab titer and vascular invasion were independent prognostic factors of disease-free survival [odds ratio (OR) 1.9, p = 0.03, and OR 1.8, p = 0.04, respectively]. Subgroup analysis identified only vascular invasion as an independent prognostic factor for early recurrences that were considered residual intrahepatic metastases. Subgroup analysis identified anti-HCV Ab titer and fibrosis grade as independent prognostic factors of late recurrences that were considered to be metachronous multicentric liver carcinogenesis (OR 4.8, p = 0.04, and OR 5.2, p = 0.03, respectively). Discussion: Anti-HCV Ab titer is a predictive factor for HCC recurrence, especially the risk of late recurrence due to multicentric carcinogenesis. Prevention of liver carcinogenesis after hepatic resection for HCC might be appropriate for patients with high anti-HCV Ab titers.

UR - http://www.scopus.com/inward/record.url?scp=84898879753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898879753&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3417-4

DO - 10.1245/s10434-013-3417-4

M3 - Article

C2 - 24464342

AN - SCOPUS:84898879753

VL - 21

SP - 1719

EP - 1725

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -